Ezetimibe in diabetes: More than cholesterol lowering

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2517-2520

  Sarigianni, Maria ^a   Katsiki, Niki ^a   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Creatinine; Diabetes; Ezetimibe; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Proteinuria; Triglycerides

Indexed keywords

ALBUMIN; ATORVASTATIN; C REACTIVE PROTEIN; CREATININE; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRITE; PITAVASTATIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTESTINE ABSORPTION; KIDNEY FUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PROTEINURIA; REVIEW; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN;

EID: 77956759830     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.518519     Document Type: Review

References (29)

1. Ruggenenti P, Cattaneo D, Rota S, et al. Effects of combined ezetimibe and simvastatin therapy as compared to simvastatin alone in patients with type 2 diabetes: a prospective, randomized, double-blind, clinical trial. Diabetes Care 2010;33:1954-1956
2. Sarigianni M, Katsiki N, Mikhailidis DP. Effects of combined ezetimibe and simvastatin therapy as compared to simvastatin alone in patients with type 2 diabetes: a prospective, randomized, double-blind, clinical trial. Diabetes Care 2010, in press
3. Yagi S, Akaike M, Aihara K, et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 2010;17:173-180
4. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009;60:525-528
5. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-2026
6. Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: The SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin 2008; 24:2467-2476
7. Migdalis I, Efthimiadis A, Pappas S, et al. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin 2009;25:2571-2576
8. Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2010, in press
9. Simons L, Tonkon M, Masana L, et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004;20:1437-1445
10. Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72
11. Berneis K, Rizzo M, Berthold HK, et al. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010;31:1633-1639
12. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipi-daemia. Curr Med Res Opin 2007;23:1169-1176
13. Tomassini JE, Mazzone T, Goldberg RB, et al. Effect of ezetimibe/simva-statin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab 2009;11: 855-864
14. Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidae-mia. Curr Vasc Pharmacol 2010, in press
15. Azar RR, Badaoui G, Sarkis A, et al. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Am J Cardiol 2010; 106:193-197
16. Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-2192
17. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375: 735-742
18. Athyros VG, Tziomalos K, Karagiannis A, et al. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010;11:1965-1970
19. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010;61:58-61
20. Yoon HE, Song JC, Hyoung BJ, et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J Intern Med 2009;24:233-237
21. Athyros VG, Kakafika AI, Karagiannis A, et al. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008;200:1-12
22. Kater AL, Batista MC, Ferreira SR. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr 2010;2:34
23. Ahmed MH, Byrne CD. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discov Today 2010;15:590-595
24. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolae-mia. Curr Med Res Opin 2008;24:1919-1929
25. Tziomalos K, Athyros VG, Karagiannis A, et al. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol 2010;8:632-637
26. Derosa G, D'Angelo A, Franzetti IG, et al. Efficacy and safety of ezetimibe/ simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J Clin Pharm Ther 2009;34:267-276
27. Landray M, Baigent C, Leaper C, et al. The second united kingdom heart and renal protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006;47:385-395
28. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009;15:490-516
29. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 2010;633:62-70